---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024119"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:52:01.112194+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Synlogic Q3 net loss $17.9M; cash $91.7M; positive Phase 2 PKU data supports Phase 3 start in H1 2023

## Summary
- Cash, cash equivalents and short-term investments of $91.7M as of Sept 30, 2022; runway into 2024.
- Q3 revenue $0.7M (vs $0.9M Q3 2021) from Roche IBD collaboration; net loss $17.9M ($0.25/sh) vs $16.0M ($0.29/sh) prior year.
- R&D expense $14.6M, G&A $4.4M, both up from prior year period.
- Positive Phase 2 'Synpheny-1' top-line data for SYNB1934/SYNB1618 in PKU; Phase 3 registrational study planned H1 2023.
- Earned research milestone from Roche collaboration for IBD Synthetic Biotic candidate.

## SEC filing metadata
- accession: 0000950170-22-024119
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000095017022024119/0000950170-22-024119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000095017022024119/sybx-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024119
- JSON: https://secwatch.observer/filing/0000950170-22-024119.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024119.txt

## Key facts
- Earnings Releases
  SYNLOGIC, INC. reported third quarter ended September 30, 2022 results: revenue $0.7 million, net income $17.9 million, EPS $0.25 per share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $0.7 million
  - Net income: $17.9 million
  - EPS: $0.25 per share
  - Result: reported results
  source text: Revenue for the three months ended September 30, 2022 was $0.7 million compared to $0.9 million for the corresponding period in 2021. Revenue in both periods was associated with the ongoing research collaboration with Roche for the discovery of a novel Synthetic Biotic for the treatment of IBD. For the three months ended September 30, 2022, Synlogic reported a consolidated net loss of $17.9 million, or $0.25 per share, compared to a consolidated net loss of $16.0 million, or $0.29 per share, for the corresponding period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527599/000095017022024119/0000950170-22-024119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.